CA-ATTACKIQ
13.4.2021 09:02:09 CEST | Business Wire | Press release
AttackIQ ®, the leading independent vendor of Breach and Attack Simulation (BAS) systems, today announced that Ross Brewer has been promoted to General Manager and Vice President of Europe, Middle East and Africa (EMEA) and Asia Pacific Japan (APJ) regions. In his new role, Brewer will be responsible for developing the strategy to expand AttackIQ’s presence in the regions, including delivering IT security and risk management leaders with solutions to identify gaps in their security posture more effectively and prioritize security initiatives more efficiently.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005210/en/
Brewer brings more than 35 years of sales and management experience with technology organizations across the globe. He previously served as strategic advisor for EMEA at AttackIQ, where he played a pivotal role in shaping the messaging and selling strategies over the last year to deliver strong growth in the financial and insurance services, oil and gas, healthcare, government, higher education, and technology sectors.
Additionally, he helped launch AttackIQ’s Academy in EMEA and APJ to provide advanced cybersecurity training, modularized curriculum, and cyberrange labs to security practitioners free of charge, in these markets. Today, more than 9,000 students in 100 countries across EMEA and APJ are continuing their cybersecurity education with AttackIQ Academy.
“CISOs around the globe recognize the importance of being adequately prepared for breaches, as the cost, complexity and frequency of cybersecurity attacks continues to exponentially increase,” said Carl Wright, Chief Commercial Officer, AttackIQ. “Ross has a proven track record of helping organizations in EMEA and APJ invest strategically in cybersecurity technology, partnerships, and practice enablement. We look forward to continuing to help security and risk leaders validate their investments and gain confidence with a threat-informed defense.”
In addition to large private and public customers throughout EMEA and APJ, including Bupa, BT, and a number of Government Ministries including Finance, Energy, Health and Sovereign Investment funds, AttackIQ has seen significant growth in the Gulf Cooperation Council (GCC) region as governments in countries like The United Arab Emirates, Kingdom of Saudi Arabia, Qatar, Oman, Kuwait and Bahrain look for cybersecurity solutions to protect their digital transformation initiatives.
As part of AttackIQ’s strategic expansion in these regions, the company signed a distribution agreement in November 2020 with Westcon-Comstor, a leading global technology distributor in the EMEA and APAC regions. Today, AttackIQ is building a presence and teams in the United Kingdom, United Arab Emirates, and Kingdom of Saudi Arabia.
“AttackIQ’s strong international growth is a direct result of its industry-leading platform, and I am excited to be joining the executive management team to continue helping organizations in these regions drive toward cybersecurity excellence,” said Brewer. “As recently noted by Gartner , breach and attack simulation is in the list of top security and risk management trends of 2021 due to its ability to help proactively identify and resolve gaps in security postures. The acceleration of c-suite leaders adopting a threat-informed defense and purple team construct with the help of AttackIQ is a direct result of leaders needing a higher level of confidence in their defensive posture.”
About AttackIQ
AttackIQ, the leading independent vendor of breach and attack simulation solutions, built the industry’s first Security Optimization Platform for continuous security control validation and improving security program effectiveness and efficiency. AttackIQ is trusted by leading organizations worldwide to plan security improvements and verify that cyberdefenses work as expected, aligned with the MITRE ATT&CK framework. The Company is committed to giving back to the cybersecurity community through its free AttackIQ Academy , open Preactive Security Exchange, and partnership with the MITRE Engenuity . For more information, visit www.attackiq.com . Follow AttackIQ on Twitter , Facebook , LinkedIn , and YouTube .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005210/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
